Kezar Life Sciences, Inc. - FORM S-1 - EX-23.1 - May 24, 2018

Attached files

file	filename
EX-21.1 - EX-21.1 - Kezar Life Sciences, Inc.	d428730dex211.htm
EX-10.14 - EX-10.14 - Kezar Life Sciences, Inc.	d428730dex1014.htm
EX-10.13 - EX-10.13 - Kezar Life Sciences, Inc.	d428730dex1013.htm
EX-10.8 - EX-10.8 - Kezar Life Sciences, Inc.	d428730dex108.htm
EX-10.7 - EX-10.7 - Kezar Life Sciences, Inc.	d428730dex107.htm
EX-10.6 - EX-10.6 - Kezar Life Sciences, Inc.	d428730dex106.htm
EX-10.5 - EX-10.5 - Kezar Life Sciences, Inc.	d428730dex105.htm
EX-10.4 - EX-10.4 - Kezar Life Sciences, Inc.	d428730dex104.htm
EX-10.3 - EX-10.3 - Kezar Life Sciences, Inc.	d428730dex103.htm
EX-10.2 - EX-10.2 - Kezar Life Sciences, Inc.	d428730dex102.htm
EX-10.1 - EX-10.1 - Kezar Life Sciences, Inc.	d428730dex101.htm
EX-4.2 - EX-4.2 - Kezar Life Sciences, Inc.	d428730dex42.htm
EX-3.4 - EX-3.4 - Kezar Life Sciences, Inc.	d428730dex34.htm
EX-3.3 - EX-3.3 - Kezar Life Sciences, Inc.	d428730dex33.htm
EX-3.2 - EX-3.2 - Kezar Life Sciences, Inc.	d428730dex32.htm
EX-3.1 - EX-3.1 - Kezar Life Sciences, Inc.	d428730dex31.htm
S-1 - S-1 - Kezar Life Sciences, Inc.	d428730ds1.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Kezar Life Sciences, Inc.:

We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG LLP

San Francisco, California

May 24, 2018